CorMedix Inc.  

(Public, NYSEMKT:CRMD)   Watch this stock  
Find more results for NYSEAMEX:CRMD
-0.13 (-4.92%)
Real-time:   2:52PM EDT
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.45 - 2.67
52 week 1.15 - 4.54
Open 2.66
Vol / Avg. 173,546.00/567,265.00
Mkt cap 94.79M
P/E     -
Div/yield     -
EPS -0.50
Shares 38.34M
Beta -0.12
Inst. own 15%
Sep 12, 2016
CorMedix Inc at Rodman & Renshaw Global Investment Conference
Aug 5, 2016
Q2 2016 CorMedix Inc Earnings Release
Aug 5, 2016
Q2 2016 CorMedix Inc Earnings Call
Jul 14, 2016
CorMedix Inc at PR Newswire and BetterInvesting (NAIC) Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -29599.27% -8655.37%
Operating margin -29753.00% -7925.56%
EBITD margin - -7918.38%
Return on average assets -60.48% -86.20%
Return on average equity -66.91% -96.80%
Employees 9 -
CDP Score - -


1430 US Highway 206 Ste 200
BEDMINSTER, NJ 07921-4602
United States - Map
+1-908-5179500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Officers and directors

Cora M. Tellez Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Randy Milby Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
James Altland Interim Chief Financial Officer
Bio & Compensation  - Reuters
Antony E. Pfaffle M.D. Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Myron M. Kaplan Director
Age: 69
Bio & Compensation  - Reuters
Janet M. Dillione Independent Director
Age: 55
Bio & Compensation  - Reuters
Matthew P. Duffy Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael W. George Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven W. Lefkowitz Independent Director
Age: 59
Bio & Compensation  - Reuters